The Potential of Lactiplantibacillus plantarum ATCC 14917 in the Development of Alginate-Based Gel Formulations with Anti–Staphylococcus aureus Properties
Pharmaceuticals · 07.08.2023 · 16 (8) · 1112
DOI: 10.3390/ph16081112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 07.08.2023. Verfasst von Monaliza Teresa Campos Sodré und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Applied Microbiology, CEUMA University, São Luís 65075-120, MA, Brazil. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Abstract (Originalsprache)
This study aimed to evaluate the potential of lactic acid bacteria (LAB) in developing alginate-based gel formulations to inhibit Staphylococcus aureus. Initially, the antagonistic actions of three lactic acid bacteria (LAB) (Lacticaseibacillus rhamnosus ATCC 10863, Lactiplantibacillus plantarum ATCC 14917, Limosilactobacillus fermentum ATCC 23271) were evaluated against S. aureus ATCC 25923. All tested LAB inhibited S. aureus, but the highest activity was observed for L. plantarum ATCC 14917 (p < 0.05). The antimicrobial effects of L. plantarum ATCC 14917 cell suspensions, sonicate cells extract, and cell-free supernatants (pH 5 or 7) were analyzed using a broth-based assay. The cell suspensions inhibited S. aureus at concentrations ≥ 10%, and these effects were confirmed by a time-kill assay. Alginate-based gels were formulated with cell suspensions, sonicate cells extract, and cell-free supernatant (pH 5). These formulations inhibited S. aureus growth. Based on the results, the alginate gel with cell suspensions at 10% was selected for further characterization. L. plantarum ATCC 14917 survived in the alginate-based gel, especially when stored at 5 °C. At this temperature, the L. plantarum-containing alginate gel was stable, and it was in compliance with microbiological standards. These findings suggest it can be a promising agent for the topical treatment of infections induced by S. aureus.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Applied Microbiology, CEUMA University, São Luís 65075-120, MA, Brazil.
- Laboratory of Microbial Pathogenesis, CEUMA University, São Luís 65075-120, MA, Brazil.
- Laboratory of Microbiology Research, Federal Institute of Education, Science and Technology of Maranhão (IFMA), São Luís 65030-005, MA, Brazil.
ORCID-Profile: Douglas Henrique Dos Santos Silva, Lucas Dos Santos Silva, Cristina Andrade Monteiro, Luis Cláudio Nascimento Silva
Förderung
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Zitieren
APA
Sodré, M. T. C., Ferraz, F. A., Alencar, A. K. V., Silva, K. F., Silva, D. H. D. S., Silva, L. D. S., Araújo Carneiro, J. S. D. S., Monteiro, C. A., Silva, L. C. N., & Monteiro, A. S. (2023). The Potential of Lactiplantibacillus plantarum ATCC 14917 in the Development of Alginate-Based Gel Formulations with Anti–Staphylococcus aureus Properties. Pharmaceuticals, 16(8), 1112. https://doi.org/10.3390/ph16081112
Vancouver
Sodré MTC, Ferraz FA, Alencar AKV, Silva KF, Silva DHDS, Silva LDS, et al. The Potential of Lactiplantibacillus plantarum ATCC 14917 in the Development of Alginate-Based Gel Formulations with Anti–Staphylococcus aureus Properties. Pharmaceuticals. 2023;16(8):1112. doi:10.3390/ph16081112
BibTeX
@article{Sodr2023,
author = {Sodré, Monaliza Teresa Campos and Ferraz, Fernanda Avelino and Alencar, Amanda Karoline Vieira and Silva, Karinny Farias and Silva, Douglas Henrique Dos Santos and Silva, Lucas Dos Santos and Araújo Carneiro, Jéssica Silva Dos Santos and Monteiro, Cristina Andrade and Silva, Luis Cláudio Nascimento and Monteiro, Andrea de Souza},
title = {The Potential of Lactiplantibacillus plantarum ATCC 14917 in the Development of Alginate-Based Gel Formulations with Anti–Staphylococcus aureus Properties},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {8},
pages = {1112},
doi = {10.3390/ph16081112}
}
EUVIMED